Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 3/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
| ▸ | HTR2B | P41595 | 2/20 | 0.39 |
| ▸ | ESR1 | P03372 | 2/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | EDNRA | P25101 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL614134 | 0.92 | ALOX15 (0.41) | ALOX15ALOX12CYP3A4ESR1ESR2 | |
| SCHEMBL615891 | 0.91 | ALOX15 (0.44) | ALOX15ALOX12CYP3A4PTGS1CYP19A1 | |
| SCHEMBL615749 | 0.91 | ALOX15 (0.47) | ALOX15ALOX12CYP3A4ESR1ESR2 | |
| SCHEMBL12055379 | 0.89 | ALOX15 (0.42) | ALOX15ALOX12CYP3A4PTGS1EDNRA | |
| SCHEMBL24103710 | 0.88 | CYP3A4 (0.44) | ALOX15ALOX12CYP3A4PTGS1 | |
| SCHEMBL616781 | 0.88 | CYP3A4 (0.44) | ALOX15ALOX12CYP3A4PTGS1 | |
| SCHEMBL30362849 | 0.88 | CYP3A4 (0.44) | ALOX15ALOX12CYP3A4PTGS1 | |
| SCHEMBL10042939 | 0.88 | CYP3A4 (0.44) | ALOX15ALOX12CYP3A4PTGS1 | |
| SCHEMBL10077378 | 0.87 | ALOX15 (0.38) | ALOX15ALOX12CYP3A4ESR1ESR2 | |
| SCHEMBL10042959 | 0.87 | ALOX15 (0.44) | ALOX15ALOX12CYP3A4PTGS1EDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120251630-A1 | REMISSION THERAPY OF CANCER WITH ISOFLAVONOIDS | MARSHALL EDWARDS, INC. (US) | 2012-10-04 | — | — | US | claimed |
| EP-1794141-B1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | MARSHALL EDWARDS INC (US) | 2011-11-09 | — | — | EP | claimed |
| US-20160287555-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | NOVOGEN RESEARCH PTY LTD (AU) | 2016-10-06 | — | — | US | disclosed |
| US-20160287555-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | NOVOGEN RESEARCH PTY LTD (AU) | 2016-10-06 | — | — | US | disclosed |
| US-9381186-B2 | Substituted chroman derivatives, medicaments and use in therapy | MEI PHARMA, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-9381186-B2 | Substituted chroman derivatives, medicaments and use in therapy | MEI PHARMA, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150352074-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | NOVOGEN RESEARCH PTY LTD (AU) | 2015-12-10 | — | — | US | disclosed |
| US-20150352074-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | NOVOGEN RESEARCH PTY LTD (AU) | 2015-12-10 | — | — | US | disclosed |
| US-9138478-B2 | Substituted chroman derivatives, medicaments and use in therapy | MEI PHARMA, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9138478-B2 | Substituted chroman derivatives, medicaments and use in therapy | MEI PHARMA, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20140170243-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | MEI PHARMA, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20100130598-A1 | METHODS FOR INDUCING PROGRAMMED CELL DEATH | NOVOGEN RESEARCH PTY LTD. (AU) | 2010-05-27 | — | — | US | disclosed |
| WO-2010045674-A1 | METHODS FOR INDUCING PROGRAMMED CELL DEATH | NOVOGEN RESEARCH PTY LTD (AU) | 2010-04-29 | — | — | WO | disclosed |
| WO-2010022467-A1 | IMMUNOMODULATING ACTIVITIES | NOVOGEN RESEARCH PTY LTD (AU) | 2010-03-04 | — | — | WO | disclosed |
| US-20090317490-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | NOVOGEN RESEARCH PTY LTD. (AU) | 2009-12-24 | — | — | US | disclosed |
| US-20090317490-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | NOVOGEN RESEARCH PTY LTD. (AU) | 2009-12-24 | — | — | US | disclosed |
| EP-2120925-A1 | METHOD FOR INDUCING AUTOPHAGY | Novogen Research Pty. Ltd. (AU) | 2009-11-25 | — | — | EP | disclosed |
| US-7601855-B2 | anticancer agents; chemotherapeutic selective agents | NOVOGEN RESEARCH PTY LTD (AU) | 2009-10-13 | — | — | US | disclosed |
| US-7601855-B2 | anticancer agents; chemotherapeutic selective agents | NOVOGEN RESEARCH PTY LTD (AU) | 2009-10-13 | — | — | US | disclosed |
| WO-2008113100-A1 | METHOD FOR INDUCING AUTOPHAGY | NOVOGEN RESEARCH PTY LTD (AU) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120251630-A1 | REMISSION THERAPY OF CANCER WITH ISOFLAVONOIDS | CYP19A1, HSD17B11, BRCA1 | ALOX15 1669/4885ALOX12 1582/4885CYP3A4 983/4885 |
| US-20150352074-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | CDYL, XPA, TP53 | ALOX15 4170/4885ALOX12 4177/4885CYP3A4 973/4885 |
| US-20140170243-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | CDYL, XPA, TP53 | ALOX15 4170/4885ALOX12 4177/4885CYP3A4 973/4885 |
| US-20090317490-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | CDYL, XPA, TP53 | ALOX15 4170/4885ALOX12 4177/4885CYP3A4 973/4885 |
| US-20100130598-A1 | METHODS FOR INDUCING PROGRAMMED CELL DEATH | CASP3, BAX, BAD | ALOX15 252/4885ALOX12 211/4885CYP3A4 3457/4885 |
| US-20160287555-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | CDYL, XPA, TP53 | ALOX15 4170/4885ALOX12 4177/4885CYP3A4 973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.